- CH₣416.88m
- CH₣632.48m
- CH₣483.90m
- 59
- 50
- 34
- 42
Annual income statement for medmix AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 351 | 457 | 477 | 487 | 484 |
| Cost of Revenue | |||||
| Gross Profit | 121 | 181 | 175 | 158 | 160 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 333 | 397 | 458 | 471 | 471 |
| Operating Profit | 18.1 | 59.9 | 19.6 | 16 | 12.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 10.5 | 51.3 | 12.2 | 2.9 | -6.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 9.7 | 44 | 11.6 | 0.7 | -6.3 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 9.7 | 44 | 11.6 | 0.3 | -7.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 9.6 | 44 | 11.6 | 0.3 | -7.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.375 | 1.09 | 0.88 | 0.24 | 0.123 |
| Dividends per Share |